ZNF160 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 6.32893737417817E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.32100000005408E-06 |
Normal-vs-Stage2 |
2.437800E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.417680E-03 |
Stage1-vs-Stage2 |
2.387400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
6.388000E-02 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
4.687800E-01 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.66100030898997E-10 |
Normal-vs-AfricanAmerican |
1.043630E-01 |
Normal-vs-Asian |
4.049900E-02 |
Caucasian-vs-AfricanAmerican |
3.036100E-02 |
Caucasian-vs-Asian |
4.304200E-01 |
AfricanAmerican-vs-Asian |
1.920190E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
2.92850000005451E-06 |
Normal-vs-Female |
4.28069999447445E-08 |
Male-vs-Female |
2.559600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
6.186400E-04 |
Normal-vs-Extreme_Weight |
1.82280000005086E-06 |
Normal-vs-Obese |
2.179200E-03 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
5.589600E-01 |
Normal_Weight-vs-Obese |
1.800190E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
2.986000E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
2.375000E-01 |
Normal-vs-Age(41-60Yrs) |
7.552200E-04 |
Normal-vs-Age(61-80Yrs) |
1.83909998341392E-09 |
Normal-vs-Age(81-100Yrs) |
3.079800E-01 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.327810E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.073810E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.055200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.390800E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.008400E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.916400E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
5.437800E-01 |
Normal-vs-Grade 3 |
5.636600E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
9.512000E-01 |
Grade 2-vs-Grade 4 |
5.437800E-01 |
Grade 3-vs-Grade 4 |
5.636600E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
2.25270002651712E-09 |
Normal-vs-N1 |
1.442210E-03 |
N0-vs-N1 |
1.579720E-02 |
|
|